계명대학교 의학도서관 Repository

Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial

Metadata Downloads
Author(s)
Dong Woo ShinJong-chan LeeJaihwan KimYoo-Seok YoonHo-Seong HanHaeryoung KimJin-Hyeok Hwang
Keimyung Author(s)
Shin, Dong Woo
Department
Dept. of Internal Medicine (내과학)
Journal Title
Pancreatology
Issued Date
2021
Volume
21
Issue
4
Keyword
Pancreatic cancerHuman equilibrative nucleoside transporter 1Gemcitabine
Abstract
Background:
The study aimed to evaluate the clinical outcomes of tailored adjuvant chemotherapy according to human equilibrative nucleoside transporter 1 (hENT1) expression in resected pancreatic ductal adenocarcinoma (PDA).

Methods:
Patients who underwent pancreatectomy for PDA were enrolled prospectively. According to intra-tumoral hENT1 expression, the high hENT1 (≥50%) group received gemcitabine and the low hENT1 (<50%) group received 5-fluorouracil plus folinic acid (5-FU/FA). The propensity score-matched control consisted of patients who received hENT1-independent adjuvant chemotherapy. The primary outcome was recurrence free survival (RFS) and the secondary outcomes were overall survival (OS) and toxicities.

Results:
Between May 2015 and June 2017, we enrolled 44 patients with resected PDA. During a median follow-up period of 28.5 months, the intention-to-treat population showed much longer median RFS [22.9 (95% CI, 11.3–34.5) vs. 10.9 (95% CI, 6.9–14.9) months, P = 0.043] and median OS [36.2 (95% CI, 26.5–45.9) vs. 22.1 (95% CI, 17.7–26.6) months, P = 0.001] compared to the controls. Among 5 patients in the low hENT1 group who discontinued treatment, 2 patients receiving 5-FU/FA discontinued treatment due to drug toxicities (febrile neutropenia and toxic epidermal necrolysis).

Conclusion:
Tailored adjuvant chemotherapy based on hENT1 staining provides excellent clinical outcomes among patients with resected PDA.
Keimyung Author(s)(Kor)
신동우
Publisher
School of Medicine (의과대학)
Citation
Dong Woo Shin et al. (2021). Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial. Pancreatology, 21(4), 796–804. doi: 10.1016/j.pan.2021.02.022
Type
Article
ISSN
1424-3903
Source
https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S1424390321000727
DOI
10.1016/j.pan.2021.02.022
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43753
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Authorize & License
  • Authorize공개
  • EmbargoForever
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.